EX-10.1




 Exhibit 10.1 

October 26, 2021 
 John M. Maraganore, Ph.D.,

     at the address on file with 

    Alnylam Pharmaceuticals, Inc. 
 Dear
John: 
 In connection with your retirement as Chief Executive Officer of Alnylam Pharmaceuticals, Inc. (the “Company”),
this letter agreement (the “Letter Agreement”) sets forth the terms of your retirement and your transition to providing consulting services to the Company. If you agree with the terms described in this Letter Agreement, which
include a general release, please sign in the space provided below and return it to me. You must also reaffirm the release and restrictive covenants in this Letter Agreement following your Transition Date and the end of your Consulting Period as
described in Paragraph No. 14(b) (collectively, your “Reaffirmations”). 
 Retirement and Transition 

1. Your retirement will become effective and your employment with the Company will end as of the close of business on December 31, 2021
(your “Transition Date”). You will be paid, at your current annual salary, for time worked through your Transition Date (and receive your full benefits through such date) and for unused and accrued vacation time (if any) as of your
Transition Date, in each case less lawful deductions, and will be reimbursed for any pre-Transition Date expenses submitted and documented to the extent such expenses are reimbursable under the Company’s
Travel & Entertainment Expense policy and/or other applicable policy. 
 2. As of your Transition Date, you will resign
automatically from your position as Chief Executive Officer and director of the Company and from all other positions as an employee, officer or director of the Company or any direct or indirect subsidiary without any further action by you or the
Company, although you further agree to sign any specific resignation letters as may be requested by the Company. 
 3. After your Transition
Date you will be entitled to participate in benefit programs offered by the Company to its employees only to the extent permitted by the terms of the Company’s plans, programs and policies. In the event that you are not eligible for the
Company’s medical or dental coverage during the Consulting Period (as defined below) and you are eligible for and properly elect to continue your medical and dental coverage under COBRA, the Company shall pay the full amount of any COBRA
premium to continue such coverage during the Consulting Period. 













			
	John M. Maraganore, Ph.D.	  	 -
 2
-

  

 Consulting Services 

4. From your Transition Date through the three-month anniversary of your Transition Date (your “Consulting Period”), under the
oversight of the Company, you agree to assist the Company as a consultant with respect to the types of matters that were subject to your purview as a Company employee, as reasonably requested by the Executive Chair of the Company, or his designee,
with reasonable advance notice (your “Consulting Services”). You agree to devote so much of your time and effort as is reasonable and adequate to perform your Consulting Services, although your Consulting Services will be limited to
ten (10) hours per month during the Consulting Period, unless otherwise mutually agreed. The Company will pay you $500 per hour or portion thereof in the event that it requests your Consulting Services beyond the ten (10) hours per month
agreed to here. You agree to comply with all lawful directions and policies of the Company while performing your Consulting Services. The Company will reimburse you for all pre-approved reasonable and
documented out-of-pocket expenses incurred by you in the provision of the Consulting Services. 

5. As compensation for your Consulting Services and as partial consideration for your other obligations and promises in this Letter Agreement,
including for the general release set forth in Paragraph No. 12, and provided you do not revoke your acceptance of this Letter Agreement or your initial Reaffirmation, in each case pursuant to Paragraph No. 15, the Company agrees that,
during your Consulting Period, the Company will pay you a monthly fee equal to one-twelfth of your current base rate of pay of $952,800 per year, payable on or before the last day of each month, commencing in
January 2022. 
 6. In addition, you will be appointed as a member of the Company’s Scientific Advisory Board (the
“SAB”) effective as of your Transition Date, subject to the same terms as the other members of the SAB, except that you will not receive any compensation for your role as a member of the SAB during your Consulting Period. 

Separation Benefits 
 7. Your retirement
will be treated as a resignation for “Good Reason” or a termination without “Cause” pursuant to the terms of your Employment Agreement, dated as of August 2, 2021, between you and the Company (your “Employment
Agreement”). 
 8. Pursuant to your Employment Agreement and as additional consideration for your obligations and promises in this
Letter Agreement, including for the general release set forth in Paragraph No. 12, and provided you do not revoke your acceptance of this Letter Agreement or either of your Reaffirmations: 













			
	John M. Maraganore, Ph.D.	  	 -
 3
-

  


	 	(a)	 Notwithstanding your retirement prior to the determination and payment of bonuses for fiscal year 2021, the
Company will pay you an annual bonus at the time 2021 bonuses under the Company’s Annual Incentive Program are paid to then-existing executive officers of the Company, which will be prior to March 15, 2022. Your annual bonus for 2021 will
be determined by the People, Culture and Compensation Committee of the Company’s Board of Directors (“Compensation Committee”) based on actual performance for 2021. 



 

	 	(b)	 Treatment of Equity Awards 



 

	 	(1)	 You will not be entitled to receive any additional equity awards after your Transition Date.



  

	 	(2)	 In accordance with Section 6(a)(i)-(ii) of your Employment Agreement, (x) your previously issued
equity awards (including but not limited to stock options and PSUs) will continue to vest until the second anniversary of the end of your Consulting Period, and (y) your stock options that are exercisable as of your Transition Date or that
become exercisable pursuant to subclause (x) will remain exercisable until the earlier of the second anniversary of the end of the Consulting Period and the original expiration dates of such options. 



 

	 	(3)	 As provided in Section 4(d) of your Employment Agreement, you will continue to have the right to exercise
your outstanding, vested and unexercised nonqualified stock options and any outstanding, vested and unexercised stock option you hold on its expiration date shall be exercised by the Company on its expiration by a “net exercise”
arrangement and with withholding satisfied by shares retained from the stock option. 


  

	 	(c)	 The Company will reimburse up to $50,000 of legal fees and expenses that you reasonably incur in connection
with the negotiation and preparation of this Letter Agreement as soon as reasonably practicable following the date hereof. 


 The Company
and you will use reasonable, good faith efforts to agree on language of internal and public statements relating to your transition and separation from the Company. 













			
	John M. Maraganore, Ph.D.	  	 -
 4
-

  

 The Company will cease providing the preceding payments and benefits upon the date of any material breach by
you of your obligations hereunder or under your Employee Nondisclosure, Noncompetition and Assignment of Intellectual Property Agreement, attached to this Letter Agreement as Exhibit A (the “NDA”). For the avoidance of
doubt, as part of the cessation of payments and benefits, all of your outstanding equity awards will stop vesting and all of your outstanding stock options will cease to be exercisable upon any such material breach. Notwithstanding the foregoing, no
breach will be treated as a material breach under this Letter Agreement, or as a violation resulting in your then vested equity awards ceasing to be exercisable, unless the Company has: (x) provided you written notice stating with reasonable
specificity the applicable facts and circumstances underlying such finding of breach or violation; and (y) provided you with an opportunity to cure (unless uncurable) any such breach or violation within thirty (30) days after the receipt
of the written notice. For the avoidance of doubt, in the event that a Change in Control (as defined in Section 5(c) of your Employment Agreement) occurs on or before the second anniversary of the end of the Consulting Period, your
then-outstanding equity awards will be treated in the same manner as the then-outstanding equity awards held by the continuing members of the Company’s Management Board. For the avoidance of doubt, notwithstanding the foregoing, all awards made
to the you prior to August 2018 are subject only to the Company’s Clawback Policy, effective December 17, 2014, attached hereto as Exhibit B. 

9. You acknowledge and agree that (1) effective upon the filing of the Company’s periodic report on Form 10-K for the year ended December 31, 2021, you will no longer be designated as an employee, nor will you be designated as a contractor or consultant that is subject to the Company’s Amended and Restated
Insider Trading Policy and (2) you understand and will comply with the restrictions under applicable securities laws regarding (a) transacting in Company securities on the basis of material nonpublic information concerning the Company and
(b) disclosing material nonpublic information to others who might transact in Company securities on the basis of that information. You agree that for the period from the issuance of the Form10-K for the
year ending December 31, 2021 to March 31, 2022, you will not transact in Company securities absent a determination by the Company’s General Counsel that you are not in possession of any material, nonpublic information. 

10. You understand and agree that you would not receive the monies and/or benefits specified in either Paragraph No. 5 or Paragraph
No. 8 above, except for your execution of this Letter Agreement and the fulfillment of the promises contained in this Letter Agreement and your Reaffirmations. You also agree that, if the Compensation Committee determines that you have engaged
in significant misconduct resulting in a violation of a significant Company policy, law, or regulation relating to manufacturing, promotion, marketing or sale of products or product candidates that causes material harm to the Company, you shall
promptly return to the Company, upon the Compensation Committee’s request, any and all payments made pursuant to Paragraph No. 5 and 8(a) and amounts realized as a result of Paragraph No. 8(b) (without impacting the validity or
enforceability of the general release contained herein); provided that in the event of such a request, you will be provided an opportunity to appeal such determination by the Compensation Committee to the Company’s Board of Directors. Further,
for the avoidance of doubt, all awards made to you prior to August 2018 are subject only to the Company’s Clawback Policy, effective December 17, 2014, attached hereto as Exhibit B. 













			
	John M. Maraganore, Ph.D.	  	 -
 5
-

  

 11. As provided in Section 4(e) of your Employment Agreement, the Indemnification
Agreement between you and the Company dated September 16, 2016 and the letter agreement between the Company and Choate, Hall & Stewart dated as of April 24, 2021 shall remain in full force and effect. 

Release and Restrictive Covenants 
 12. In
consideration of the payments to be made and the benefits to be provided by the Company to you as set forth in Paragraph No. 5 and Paragraph No. 8 above and the promises contained in this Letter Agreement, you voluntarily and of your own
free will hereby release, forever discharge and hold harmless Alnylam Pharmaceuticals, Inc., its subsidiaries, divisions and affiliates, its present or former officers, directors, trustees, employees, agents, insurers, or successors or assigns from
any and all claims, demands, rules or regulations, or any other causes of action of whatever nature, whether known or unknown, through the date you execute this Letter Agreement, including, but not limited to, the National Labor Relations Act, as
amended; Title VII of the Civil Rights Act of 1964, as amended; Sections 1981 through 1988 of Title 42 of the United States Code, as amended; the Age Discrimination in Employment Act of 1967, as amended; the Older Workers Benefit Protection Act; the
Immigration Reform Control Act, as amended; the Employee Retirement Income Security Act of 1974, 29 U.S.C.§ 1001, et seq.; the Occupational Safety and Health Act, as amended; the Civil Rights Act of 1866, 29 U.S.C. § 1981, et
seq.; the Rehabilitation Act of 1973, 29 U.S.C. § 701, et seq.; the Americans With Disabilities Act of 1990, as amended; the Civil Rights Act of 1991; the Family and Medical Leave Act; the Equal Pay Act; the Massachusetts Law Against
Discrimination, G.L. c. 151B; the Massachusetts Wage Payment Statute, G.L. c. 149, §§ 148, 148A, 148B, 149, 150, 150A-150C, 151, 152, 152A, et seq.; the Massachusetts Wage and Hour Laws, G.L. c. 151 § 1A et seq.; the
Massachusetts Privacy Statute, G.L. c. 214, § 1B; the Massachusetts Wage Payment Statute, G.L. c. 149, § 148 et seq.; the Massachusetts Sexual Harassment Statute, G.L. c. 214 § 1C; the Massachusetts Civil Rights Act, G.L. c.
12, § 11H, the Massachusetts Equal Rights Act, G.L. c. 93, § 102; the Massachusetts Equal Pay Act, G.L. c. 149, § 105A; the Massachusetts Parental Leave Law, G.L. c. 149, § 105D; the Massachusetts Family and Medical Leave Law,
G.L. c. 175M; or any other federal or state law, regulation, or ordinance; any public policy, contract, tort, or common law; or any allegation for costs, fees, or other expenses including attorneys’ fees incurred in these matters. In addition,
if any claim is not subject to release, to the extent permitted by law, you waive any right or ability to be a class or collective action representative or to otherwise participate in any putative or certified class, collective or multi-party action
or proceeding based on such a claim in which the Company or any other releasee identified in this Letter Agreement is a party. 













			
	John M. Maraganore, Ph.D.	  	 -
 6
-

  

 Notwithstanding the foregoing, you are not waiving any rights you may have to (a) your
own vested accrued employee benefits, including under the Company’s retirement benefit plan(s); outstanding equity awards (e.g. stock options and PSUs) granted to you that are vested as of the date hereof or that vest under Paragraph No.8(b)(2)
above and related agreements entered into with you under the Company’s Equity Plans; and your right to reimbursement for any out-of-pocket business expenses
authorized to be incurred and reimbursed pursuant to Company policies, as of your Transition Date, (b) rights pursuant to the Indemnification Agreement (and the related letter agreement between the Company and Choate, Hall & Stewart
referenced above), for the term specified therein and any other rights, to the extent applicable, for defense and indemnification for actions taken by you in the course and scope of your employment with the Company and/or its subsidiaries and
affiliates; (c) benefits and/or the right to seek benefits under applicable workers’ compensation and/or unemployment compensation statutes; (d) pursue claims which by law cannot be waived by signing this Letter Agreement;
(e) enforce this Letter Agreement; and/or (f) challenge the validity of this Letter Agreement. 
 13. The covenants in
Section 7 of your Employment Agreement regarding your nondisclosure and noncompetition, as well as and your and the Company’s cooperation and mutual non-disparagement, shall remain in full force and
effect. Nothing in this Letter Agreement prohibits or prevents (i) you from providing information to, or testifying or assisting in any investigation, hearing or proceeding before, any federal, state, or local government agency or official,
including (without limitation) with respect to the investigatory response to the subpoena from the U.S. Attorney’s Office for the District of Massachusetts, as well as courts of law; provided that such information is not protected by the
attorney-client privilege owned by the Company, which privilege can only be waived by the Company or (ii) the Company, its Board of Directors and its employees from providing information to, or testifying or assisting in any investigation,
hearing or proceeding before, any federal, state, or local government agency or official, including (without limitation) with respect to the investigatory response to the subpoena from the U.S. Attorney’s Office for the District of
Massachusetts, as well as courts of law. In further consideration for the monies and benefits provided to you in this Letter Agreement, by signing this Letter Agreement, you are reaffirming the post-employment restrictive covenants and the other
terms and conditions of your NDA, as set forth herein, provided, however, that you may employ your executive assistant. You understand that the Company would not provide you with the monies and benefits under this Letter Agreement but for your
acknowledgment and reaffirmation of these obligations under your NDA. You also affirm that, except as otherwise agreed in writing by the Company’s Chief Human Resources Officer (or a duly authorized representative of the Company), you will
return to the Company all Company keys, files, records (and copies thereof), equipment (including, but not limited to, computer hardware, software, printers, wireless handheld devices, cellular phones, etc.), Company identification, and any other
Company-owned property otherwise in your possession or control, on or before December 31, 2021, and have left intact, and will for so long as you have access continue to keep intact, all electronic Company documents in your possession or
control, including but not limited to, those that you developed or helped develop during your employment. Violation of this paragraph shall be deemed a material breach of this Letter Agreement. 













			
	John M. Maraganore, Ph.D.	  	 -
 7
-

  

 14. (a) You acknowledge that you have been afforded until November 16, 2021, a period of
at least twenty-one (21) days, to consider the meaning and effect of this Letter Agreement. You are advised to consult with an attorney, and you acknowledge that you have had the opportunity to do so. You
agree that any modifications, material or otherwise, do not restart or affect in any manner the original consideration period for the proposal made to you by the Company. 

      (b) In addition, you must reaffirm Paragraphs No. 12 and 13 as of your Transition Date and the end of
your Consulting Period (as defined above, your “Reaffirmation”). If your Reaffirmation does not become effective by your revocation pursuant to Paragraph No. 15, you will not be eligible to receive the monies and benefits set
forth in either Paragraph No. 5 or Paragraph No. 8 above. 
 15. You may revoke your acceptance of Paragraphs No. 4 through 14
of this Letter Agreement for a period of seven (7) calendar days following the day you sign it, and you may revoke your Reaffirmation for a period of seven (7) calendar following the day you sign your Reaffirmation. Any revocation must be
submitted, in writing, to Kelley Boucher, Chief Human Resources Officer and state, “I hereby revoke [my acceptance] [my reaffirmation] of Paragraphs No. 4 through 14 of the Letter Agreement, including the general
release.” The revocation must be personally delivered by email to kboucher@alnylam.com within such seven (7) calendar day period. Paragraphs No. 4 through 14 of this Letter Agreement, or Reaffirmation thereof (as the case may be),
shall not become effective or enforceable until the revocation period has expired with no revocation by you received by the Company. If the last day of the revocation period is a Saturday, Sunday, or legal holiday in Massachusetts then the
revocation period shall not expire until the next following day which is not a Saturday, Sunday, or legal holiday. 
 Additional Provisions 

16. This Letter Agreement, which will be construed under Massachusetts law, may not be modified, altered, or changed except upon express
written consent of both parties wherein specific reference is made to this Letter Agreement. The parties agree to use confidential arbitration in accordance with Section 13 of your Employment Agreement. 













			
	John M. Maraganore, Ph.D.	  	 -
 8
-

  

 17. Except as previously disclosed to the Company, you hereby warrant that as of the date you
sign this Letter Agreement, you have not commenced, filed, participated in, offered testimony, or assisted any other investigation, hearing, or any proceeding before any federal, state, or local government agency relating to or against the Company.
You further warrant that you have disclosed, or will disclose prior to the execution of this Letter Agreement, any and all known violations of law during your tenure at the Company. Nothing in this Letter Agreement prohibits or prevents you from
filing a charge with or participating, testifying, or assisting in any investigation, hearing, or other proceeding before the U.S. Equal Employment Opportunity Commission, the National Labor Relations Board or a similar agency enforcing federal,
state or local anti-discrimination laws. However, to the maximum extent permitted by law, you agree that if such an administrative claim is made to such an anti-discrimination agency, you will not be entitled to recover any individual monetary
relief or other individual remedies. In addition, nothing in this Letter Agreement, including but not limited to the release of claims and the confidentiality and non-disparagement clauses, or the NDA
prohibits you from: (1) reporting possible violations of federal law or regulations, including any possible securities laws violations, to any governmental agency or entity, including but not limited to the U.S. Department of Justice, the
Securities and Exchange Commission, the U.S. Congress, or any agency Inspector General; (2) making any other disclosures that are protected under the whistleblower provisions of federal law or regulations; or (3) otherwise fully
participating in any federal whistleblower programs, including but not limited to any such programs managed by the Securities and Exchange Commission and/or the Occupational Safety and Health Administration. Moreover, nothing in this Letter
Agreement prohibits or prevents you from receiving individual monetary awards or other individual relief by virtue of participating in such federal whistleblower programs. 

18. You affirm that you have been paid and have received all leave (paid or unpaid), compensation, wages, bonuses, commissions, severance pay,
and/or benefits to which you may be entitled and that no other leave (paid or unpaid), compensation, wages, bonuses, commissions, severance pay, and/or benefits are due to you, except as provided in this Letter Agreement. You further affirm that you
have no known workplace injuries or occupational diseases and have been provided and/or have not been denied any leave requested under the Family and Medical Leave Act. You also affirm that you have not been retaliated against for reporting any
allegations of wrongdoing by the Company or its officers. In addition, you affirm that all decisions regarding your pay and benefits through the date of your signature of this Letter Agreement were not discriminatory based on age, disability, race,
color, sex, religion, national origin or any other classification protected by law. 
 19. The parties agree that neither this Letter
Agreement, nor the furnishing or acceptance of consideration for this Letter Agreement, shall be deemed or construed at any time for any purpose as an admission by you or the Company of any liability or unlawful conduct of any kind. Should any
provision of this Letter Agreement be declared illegal or unenforceable by any court of competent jurisdiction and cannot be modified to be enforceable, excluding the general release language, such provision shall immediately become null and void,
leaving the remainder of this Letter Agreement in full force and effect. However, if the general release is found to be invalid, you agree to execute a valid release of the claims which are the subject of this Letter Agreement and/or are referred to
in the general release paragraph above. 













			
	John M. Maraganore, Ph.D.	  	 -
 9
-

  

 20. After you execute this Letter Agreement, neither you nor your attorneys, or any person
acting by, through, under or in concert with you or them, shall disclose any of the terms of or amount paid under this Letter Agreement or the negotiation thereof to any individual or entity (other than to state that the Company has filed this
Letter Agreement as a public document); provided, however, that the foregoing shall not prevent such disclosures by you to your attorney, financial and tax advisors and/or your spouse, or as may be required by law. Notwithstanding the
confidentiality obligations set forth in this paragraph or elsewhere in this Letter Agreement, you understand that, pursuant to the Defend Trade Secrets Act of 2016 (“DTSA”), you will not be held criminally or civilly liable under
any federal or state trade secret law for the disclosure of a trade secret (as opposed to information protected from disclosure by the attorney-client privilege) that: (A) is made (i) in confidence to a federal, state, or local government
official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding,
if such filing is made under seal. You further understand that if a court of law or arbitrator determines that you misappropriated Company trade secrets willfully or maliciously, including by making permitted disclosures without following the
requirements of the DTSA as detailed in this paragraph, then the Company may be entitled to an award of exemplary damages and attorneys’ fees against you. 

21. This Letter Agreement, which includes a general release, represents the complete agreement between you and the Company, and fully
supersedes any prior agreements or understandings between the parties other than (a) your Employment Agreement, (b) your NDA and (c) your Indemnification Agreement and the letter agreement between the Company and Choate,
Hall & Stewart referred to herein. Further, for the avoidance of doubt, (i) your rights and responsibilities with respect to outstanding stock options held by you on the date of the Employment Agreement shall be governed by the terms
of the award agreement pursuant to which such options were granted, the Company’s 2018 Equity Plan and related policies in effect on the date of the Employment Agreement as modified therein and (ii) all awards made to you prior to August
2018 are subject to only the Company’s Clawback Policy, effective December 17, 2014, attached as Exhibit B. 
 22.
You acknowledge that you have not relied on any representations, promises, or agreements of any kind made to you in connection with your decision to sign this Letter Agreement, except those set forth in this Letter Agreement. In deciding to enter
into this Letter Agreement, you acknowledge that you are not relying upon a legal duty, if one exists, on the part of the Company (or the Company’s employees, agents, representatives or attorneys) to disclose any information in connection with
the execution of this Letter Agreement or its preparation. It is expressly understood that you shall never assert any failure to disclose information on the part of the Company as a ground for challenging the validity of this Letter Agreement. 













			
	John M. Maraganore, Ph.D.	  	 -
 10
-

  

 23. The Company may withhold from any amounts or benefits payable under this Letter Agreement
income taxes and payroll taxes that are required to be withheld pursuant to any applicable law or regulation. 
 24. This Letter Agreement
may be signed in counterparts, each of which when so signed shall be deemed an original, and the counterparts together shall constitute one and the same agreement. A copied, scanned or faxed signature shall be treated the same as an original. 

25. Although the Company does not guarantee the tax treatment of any payments under this Letter Agreement, the intent of the parties is that
the payments and benefits hereunder be exempt from, or comply with, Section 409A of the Internal Revenue Code of 1986, as amended, and all Treasury Regulations and guidance promulgated thereunder (“Code
Section 409A”) and to the maximum extent permitted this Letter Agreement shall be limited, construed and interpreted in accordance with such intent. In no event whatsoever shall the Company or its affiliates or their
respective officers, directors, employees or agents be liable for any additional tax, interest or penalties that may be imposed on you by Code Section 409A or damages based upon payments and/or benefits payable hereunder not being exempt from
or not complying with Code Section 409A, unless such failure is due to breach of this Letter Agreement by the Company. If a payment made under this Letter Agreement that is nonqualified deferred compensation subject to Code Section 409A
may be made in more than one taxable year depending on when you sign this Letter Agreement, payment shall be made in the second taxable year. Notwithstanding any other provision of this Letter Agreement to the contrary, to the extent that any
reimbursement of expenses constitutes “deferred compensation” under Code Section 409A, such reimbursement shall be provided no later than December 31 of the year following the year in which the expense was incurred. The amount of
expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any subsequent year. The amount of any in-kind benefits provided in one year shall not affect the amount of in-kind benefits provided in any other year. For purposes of Code Section 409A (including, without limitation, for purposes of Treasury Regulation
Section 1.409A-2(b)(2)(iii)), the right to receive payments in the form of installment payments shall be treated as a right to receive a series of separate payments and, accordingly, each installment
payment shall at all times be considered a separate and distinct payment. Whenever a payment under this Letter Agreement may be paid within a specified period, the actual date of payment within the specified period shall be within the sole
discretion of the Company. Notwithstanding any other provision of this Agreement to the contrary, if at the time of your separation from service (as defined in Code Section 409A), you are a “Specified Employee”, then the Company will
defer the payment or commencement of any nonqualified deferred compensation subject to Code Section 409A payable upon separation from service (without any reduction in such 













			
	John M. Maraganore, Ph.D.	  	 -
 11
-

  

 
payments or benefits ultimately paid or provided to you) until the date that is six (6) months following separation from service or, if earlier, the earliest other date as is permitted under
Code Section 409A (and any amounts that otherwise would have been paid during this deferral period will be paid in a lump sum on the day after the expiration of the six (6) month period or such shorter period, if applicable). You will be a
“Specified Employee” for purposes of this Letter Agreement if, on the date of your separation from service, you are an individual who is, under the method of determination adopted by the Company designated as, or within the category of
employees deemed to be, a “Specified Employee” within the meaning and in accordance with Treasury Regulation Section 1.409A-1(i). 

The Company would like to extend its profound gratitude and appreciation to you for your leadership and countless contributions to the success
of the Company over many years of service, and would also like to express its sincere hope for success in your next chapter. 
  

			
	Very truly yours,
	
	/s/ Amy W. Schulman
	Name:	 	Amy W. Schulman
	Title:	 	People, Culture and Compensation Committee Chair















			
	John M. Maraganore, Ph.D.	  	 -
 12
-

  

 You have been advised in writing that you have a period of more than twenty-one (21) days to consider the release in this Letter Agreement, and that it must be signed and returned to be effective. You have also been advised to consult with an attorney prior to the execution of
this Letter Agreement. 
 Having elected to execute this Letter Agreement, to fulfill the promises set forth in this Letter Agreement, and
to receive thereby the payments and benefits set forth in Paragraph No. 5 and Paragraph No. 8 above, you freely and knowingly, and after due consideration, enter into this Letter Agreement intending to waive, settle, and release all claims
you have or might have against the Company, its subsidiaries, divisions and affiliates, its present or former officers, directors, trustees, employees, agents, insurers, or successors or assigns, as set forth herein. 

 

	
	Date: 10/26/2021
	
	 /s/ John M. Maraganore, Ph.D.

John M. Maraganore, Ph.D.